Clinical trial · Interventional
Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy
Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Small Cell Lung Cancer
NCT02011087CI-TRIAL-00033626terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow Accruals
Summary
Brief summary (as posted)
This clinical trial studies bioelectrical impedance phase angle in predicting treatment outcome in patients with extensive stage small cell lung cancer receiving first-line chemotherapy. Diagnostic procedures, such as bioelectrical impedance analysis, may help predict a patient's response to treatment for small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extensive Stage Small Cell Lung Cancer | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bioelectric impedance analysis | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (bioelectric impedance analysis)
- description
- Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
- interventionNames
- Procedure: bioelectric impedance analysis
Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- From the start of treatment to the time of progression, death, or date of last contact, assessed up to 2 years
- description
- Analyzed using Kaplan-Meier plots and a log-rank test to test the difference in progression-free survival and high/low phase angle measures.
- measure
- Standardized phase angle measure
- timeFrame
- Baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * A primary histopathological and/or cytopathological diagnosis of small cell lung cancer (SCLC) * Diagnosis of extensive stage disease (extensive stage \[ES\]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan * Scheduled to receive front-line platinum-based chemotherapy with carboplatin or cisplatin plus etoposide * Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document Exclusion Criteria: * No recent chemotherapy or surgery, as defined as in the last 6 months * Presence of a pacemaker or defibrillator * Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis * Patients with body mass index (BMI) greater than 34 or less than 16 * Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients * Unable or unwilling to follow protocol requirements * Pregnant women are excluded from participation due to inability to participate in required chemotherapy regimen
References
Publications (0)
Data not yet available
No reference posted for this study.